Consensus Humacyte, Inc.

Equities

HUMA

US44486Q1031

Market Closed - Nasdaq Other stock markets 01:30:00 14/05/2024 am IST			5-day change	1st Jan Change
5.48 ^USD	+16.60%		+20.70%	+92.96%

10/05	Transcript : Humacyte, Inc., Q1 2024 Earnings Call, May 10, 2024
28/03	Transcript : Humacyte, Inc. - Special Call

Evolution of the average Target Price on Humacyte, Inc.

Price target over the last 5 years

History of analyst recommendation changes

81019b40db859d10cb5d7a6c36db7e7.fltMOPAF0GOeRncQNOK_TjWVsCayMqfRejsfgQACMJ0.Gio9CMl0pVDKC09hZNv2PEyl0nDUfPe9QlFp5kNyQvYxGQJKhkzpFPAhTw~8816f2d8242710b98c700e1958ece4db

Analyst Recommendations on Humacyte, Inc.

Piper Sandler Adjusts Price Target on Humacyte to $4 From $3, Maintains Neutral Rating	08/03	MT
HC Wainwright Initiates Humacyte With Buy Rating, Price Target is $6	11/12	MT
Humacyte, Inc. Announces Publication of Biological Mechanism Explaining Low Rates of Infection Observed in Clinical Study of Human Acellular Vessel	03/23/03	CI
Cantor Fitzgerald Initiates Humacyte at Overweight Rating With $6 Price Target	22/23/22	MT
BTIG Adjusts Humacyte's Price Target to $10 from $12, Keeps Buy Rating	18/22/18	MT
Piper Sandler Double Downgrades Humacyte to Underweight From Overweight, Adjusts Price Target to $4 From $10	16/22/16	MT
Cowen Starts Humacyte at Outperform With $17 Price Target	29/21/29	MT
HUMACYTE : Oppenheimer Starts Humacyte at Outperform with $16 Price Target	24/21/24	MT
HUMACYTE : BTIG Starts Humacyte at Buy with $19 Price Target	22/21/22	MT
HUMACYTE : Piper Sandler Starts Humacyte at Overweight With $17 Price Target	16/21/16	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

5.48 USD

Average target price

7.667 USD

Spread / Average Target

+39.90%

High Price Target

15 USD

Spread / Highest target

+173.72%

Low Price Target

4 USD

Spread / Lowest Target

-27.01%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Humacyte, Inc.

Piper Sandler
HC Wainwright
Cantor Fitzgerald
BTIG
Cowen
Oppenheimer

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar